Last Updated: November 16, 2026

Investigational Drug Information for Cilofexor

« Back to Dashboard


What is the development status for investigational drug Cilofexor?

Cilofexor is an investigational drug.

There have been 10 clinical trials for Cilofexor. The most recent clinical trial was a Phase 2 trial, which was initiated on March 27th 2019.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Cholangitis. The leading clinical trial sponsors are Gilead Sciences, Novo Nordisk A/S, and [disabled in preview].

There are two hundred and thirty-two US patents protecting this investigational drug and two hundred and eighty-four international patents.

Recent Clinical Trials for Cilofexor
TitleSponsorPhase
Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)Novo Nordisk A/SPhase 2
Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)Gilead SciencesPhase 2
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisGilead SciencesPhase 1

See all Cilofexor clinical trials

Clinical Trial Summary for Cilofexor

Top disease conditions for Cilofexor
Top clinical trial sponsors for Cilofexor

See all Cilofexor clinical trials

US Patents for Cilofexor

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cilofexor ⤷  Start Trial FXR agonists and methods for making and using Salk Institute for Biological Studies (La Jolla, CA) ⤷  Start Trial
Cilofexor ⤷  Start Trial FXR (NR1H4) binding and activity modulating compounds GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Start Trial
Cilofexor ⤷  Start Trial FXR (NR1H4) modulating compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
Cilofexor ⤷  Start Trial FXR (NR1H4) modulating compounds Gilead Sciences Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cilofexor

Drugname Country Document Number Estimated Expiration Related US Patent
Cilofexor Australia AU2015229072 2034-03-13 ⤷  Start Trial
Cilofexor Canada CA2942403 2034-03-13 ⤷  Start Trial
Cilofexor European Patent Office EP3116878 2034-03-13 ⤷  Start Trial
Cilofexor Japan JP2017510572 2034-03-13 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Cilofexor Development Update, Patent Outlook and Market Projection

Last updated: September 4, 2026

Cilofexor, also known as GS-9674, is an oral, nonsteroidal farnesoid X receptor agonist developed by Gilead Sciences. The candidate has generated clinical activity in primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH), but it has not reached Phase 3 registration or FDA approval. Its commercial value depends on whether Gilead can establish a clinical benefit beyond biochemical improvements, particularly in PSC.

The base-case projection is that cilofexor remains a high-risk, specialty hepatology asset with no near-term revenue. If approved for PSC, peak global sales could plausibly reach $200 million to $600 million under a focused orphan-disease launch. A broader indication in MASH could raise the opportunity substantially, but current competitive and clinical conditions make that outcome unlikely without combination therapy or new efficacy data.

What is cilofexor and how does it work?

Cilofexor is a selective, nonsteroidal FXR agonist. FXR regulates bile-acid synthesis, hepatic lipid metabolism, glucose signaling and inflammatory pathways. The drug is designed for oral administration and has been evaluated primarily in liver diseases involving cholestasis, fibrosis and metabolic dysfunction.

Attribute Cilofexor
Developer Gilead Sciences
Former development code GS-9674
Drug class Nonsteroidal FXR agonist
Administration Oral
Main development areas PSC; NASH/MASH; advanced liver disease
FDA status No approval identified
Commercial status Not marketed
Orange Book status No listed product identified
Biosimilar relevance None; cilofexor is a small molecule
Main safety issue Pruritus and lipid changes associated with FXR activation

Cilofexor differs mechanistically from obeticholic acid, the former Intercept Pharmaceuticals FXR agonist. Cilofexor was designed to retain FXR activity while limiting some of the tolerability and lipid effects associated with steroidal FXR agonism.

What is the current development status of cilofexor?

Cilofexor remains an investigational drug. The strongest public development rationale is in PSC, a rare cholestatic liver disease with no broadly accepted FDA-approved disease-modifying treatment in the United States.

Gilead has reported Phase 2 data showing reductions in alkaline phosphatase and other markers of cholestasis. These results support biological activity but do not, by themselves, establish improved transplant-free survival, reduced progression to cirrhosis or delayed hepatic decompensation.

Primary sclerosing cholangitis

Cilofexor has been studied in randomized Phase 2 PSC trials, including the PRIMIS program. Reported findings included:

  • Reductions in alkaline phosphatase, a commonly used biochemical marker in PSC.
  • Effects on gamma-glutamyl transferase and other cholestatic biomarkers.
  • Limited or inconsistent improvement in patient-reported pruritus.
  • Treatment-emergent pruritus and lipid abnormalities consistent with the FXR class.
  • No publicly established Phase 3 registration package as of the latest company and trial disclosures reviewed.

PSC development is clinically difficult because alkaline phosphatase is an imperfect surrogate for long-term outcomes. A registration strategy would likely require a well-controlled trial using a validated surrogate endpoint, a composite clinical endpoint, or a combination of both.

NASH and MASH

Cilofexor was also evaluated in patients with NASH, including patients with bridging fibrosis and compensated cirrhosis. Studies examined cilofexor alone and in combination with firsocostat, Gilead's investigational ACC inhibitor.

The NASH program showed pharmacodynamic activity, including changes in liver fat, cholestatic markers and fibrosis-related biomarkers. The development case was weakened by:

  • Pruritus and lipid effects.
  • The absence of a clear standalone histologic advantage sufficient for approval.
  • Intensifying competition from incretin-based therapies.
  • Gilead's broader strategic shift away from several late-stage NASH programs.
  • The failure of earlier Gilead candidates, including selonsertib, to produce durable regulatory success in advanced NASH.

Cilofexor is therefore more commercially relevant as a PSC asset than as a standalone MASH drug.

When could cilofexor reach the market?

No reliable approval date can be assigned because cilofexor has not established a late-stage regulatory path. A realistic timeline depends on whether Gilead restarts or expands development.

Development scenario Earliest plausible U.S. filing Earliest plausible launch Probability assessment
PSC Phase 3 restarted promptly 2027-2028 2028-2029 Low to moderate
Additional Phase 2 or biomarker work 2029 or later 2030 or later Moderate
Program remains inactive None None Material risk
MASH combination development resumes 2029 or later 2030 or later Low

A PSC approval would require more than another short-duration biomarker study. Gilead would need to demonstrate a clinically meaningful benefit, manage pruritus and lipid changes, and define the appropriate treatment population.

What FDA regulatory status does cilofexor have?

Cilofexor has no FDA approval and no approved labeling. It therefore has no FDA-recognized indication, dosage, contraindication or commercial exclusivity period.

The candidate has received regulatory attention through clinical development in rare liver diseases, but a fast-track or orphan designation would not establish market exclusivity by itself. A designation could reduce review time or provide development support, but approval would still depend on clinical efficacy and safety.

What is the Orange Book status of cilofexor?

No Orange Book-listed cilofexor product has been identified. The practical consequences are significant:

  • There is no approved reference listed drug.
  • There is no ANDA pathway currently available against cilofexor.
  • No Paragraph IV litigation is publicly associated with an approved cilofexor product.
  • No FDA-listed use code or approved method-of-use patent can currently block generic filing.
  • Any future generic challenge would follow approval and listing of relevant patents.

Cilofexor is a small molecule, so the relevant future competition would be generic rather than biosimilar competition.

What patents protect cilofexor?

Cilofexor is expected to be covered by Gilead-owned or Gilead-controlled patent families directed to:

  1. The cilofexor chemical compound.
  2. FXR agonist compositions.
  3. Pharmaceutical formulations.
  4. Methods of treating cholestatic liver diseases.
  5. Methods of treating NASH, fibrosis or related hepatic disorders.
  6. Combination use with other metabolic or antifibrotic agents.

The core composition-of-matter family appears to originate from filings made during the early 2010s. On a standard 20-year term from the earliest effective nonprovisional filing, a basic composition patent would be expected to expire around 2032-2034, subject to terminal disclaimers, patent-term adjustment, patent-term extension and jurisdiction-specific rules.

How strong is the cilofexor patent estate?

The estate is strategically useful but not yet commercially tested. Its strength is likely highest for the active compound and lower for broad disease-method claims.

Patent category Expected strength Commercial relevance
Composition of matter Highest Primary barrier to generic entry
Salt, crystal and solid-state claims Moderate to high May delay substitution if independently valid
Formulation claims Moderate Relevant if the approved product uses a protected formulation
PSC method claims Moderate Useful for branded positioning; vulnerable to claim-construction issues
MASH method claims Moderate to low Broad disease claims may face enablement and obviousness challenges
Combination claims Variable Important for future combination regimens
Manufacturing claims Variable Can increase supply-chain barriers but rarely prevents all generic production

A complete patent expiration analysis requires claim-level review of each U.S., European and other national family member. The absence of an Orange Book listing means the current patent estate has no direct generic-litigation effect.

What patent litigation and Paragraph IV challenges affect cilofexor?

No public Paragraph IV litigation involving an approved cilofexor product has been identified. The reason is procedural: cilofexor has not been approved and has no Orange Book reference product.

Future litigation risk would arise in three stages:

  1. Pre-approval patent disputes: licensing, ownership, inventorship or freedom-to-operate disputes.
  2. Post-approval patent challenges: ANDA Paragraph IV notices against listed patents.
  3. Launch litigation: district-court litigation seeking a 30-month stay and, if necessary, preliminary relief.

Potential generic entry could occur before the nominal expiry of the core patent if a challenger wins invalidity or noninfringement arguments, if the relevant patent is not listed, or if the generic launches at risk.

What formulations are protected by cilofexor patents?

Public clinical development has centered on oral cilofexor tablets or tablet-like oral dosage forms. The commercially important formulation questions are:

  • Whether the final product requires a specific solid form.
  • Whether food affects absorption.
  • Whether a formulation improves tolerability or exposure.
  • Whether the approved dose differs from the clinical-trial dose.
  • Whether a fixed-dose combination with firsocostat or another agent is pursued.

Formulation patents are less valuable than composition patents unless they cover the only commercially viable dosage form. They can still extend market protection after compound-patent expiry, particularly if the product has a differentiated release profile or fixed-dose combination.

Which companies are challenging cilofexor commercially?

No company is currently challenging cilofexor through an approved generic or biosimilar pathway. Competitive pressure comes from other liver-disease therapies and investigational agents.

PSC competitors

The PSC market includes:

  • Ursodeoxycholic acid, used off-label in some markets despite limited evidence for disease modification.
  • Norursodeoxycholic acid and other investigational bile-acid therapies.
  • Immunomodulators and antifibrotic agents in clinical development.
  • Liver transplantation for advanced disease.

The leading commercial advantage for the first approved disease-modifying PSC therapy would be the absence of an established FDA-approved competitor. That advantage would be constrained by PSC's small diagnosed population and the need for long-term outcome evidence.

MASH competitors

MASH competition is substantially more intense. Relevant competitors include:

  • Resmetirom, approved by the FDA in 2024 for adults with noncirrhotic NASH with moderate to advanced fibrosis, marketed by Madrigal Pharmaceuticals.
  • Semaglutide and other GLP-1 or incretin-based therapies used for obesity and diabetes, with expanding liver-disease evidence.
  • Lanifibranor and other investigational metabolic or antifibrotic drugs.
  • Combination regimens involving FXR, ACC, GLP-1 and thyroid hormone receptor pathways.

Resmetirom materially reduces the probability that cilofexor would capture a large standalone MASH market. A cilofexor combination could remain relevant if it demonstrates additive fibrosis or clinical-outcome benefits.

What is the cilofexor market projection?

PSC scenario

PSC is a rare disease, but an approved therapy could command specialty pricing. A reasonable commercial framework is:

Scenario Treated patients globally Annual net price Peak annual sales
Conservative 3,000-5,000 $40,000-$60,000 $120 million-$300 million
Base case 6,000-10,000 $50,000-$70,000 $300 million-$700 million
Upside 10,000-15,000 $60,000-$90,000 $600 million-$1.35 billion

The base case assumes approval in PSC, use in patients with persistent cholestasis, favorable reimbursement and no superior competitor. A more realistic risk-adjusted value is materially lower because cilofexor has not entered a confirmed registration trial.

MASH scenario

The MASH opportunity is larger in patient count but less favorable for cilofexor. A successful combination product could reach annual sales above $1 billion, but that outcome would require:

  • Demonstration of histologic or clinical benefit.
  • Competitive efficacy against resmetirom and incretin therapies.
  • Acceptable pruritus and lipid profiles.
  • A differentiated treatment population.
  • A viable combination-development and reimbursement strategy.

The probability-adjusted commercial value of cilofexor in MASH is therefore below the headline market size. PSC offers a smaller but more defensible market.

How does cilofexor compare with obeticholic acid?

Factor Cilofexor Obeticholic acid
Developer Gilead Intercept
FXR type Nonsteroidal agonist Steroidal agonist
Main liver focus PSC and NASH PBC and NASH
U.S. approval None PBC approval; NASH application rejected
Key safety concerns Pruritus, lipid changes Pruritus, lipid changes, liver-safety concerns
Current commercial position No marketed product PBC commercial rights and status changed after Intercept transaction
PSC opportunity Investigational Not a leading active development path
Generic exposure None currently Depends on approved-product patent and regulatory status

Cilofexor's nonsteroidal structure may offer pharmacologic advantages, but it has not produced a regulatory outcome that clearly separates it from the broader FXR class.

What generic launch risks exist for cilofexor?

Generic launch risk is currently theoretical because there is no approved product. If approved, the principal risks would be:

  • Early Paragraph IV filing after Orange Book listing.
  • Invalidity challenges to compound or polymorph patents.
  • Noninfringement arguments against method-of-use claims.
  • Limited enforceability of broad PSC or MASH treatment claims.
  • Generic use for unpatented indications under a skinny-label strategy.
  • Patent-term expiry near the early-to-mid 2030s for early compound filings.

The most durable protection would come from a late-filed, clinically necessary formulation or combination patent, although such patents would face scrutiny if they merely restate routine formulation or dosing choices.

What licensing deals affect cilofexor?

Cilofexor has been developed within Gilead's internal pipeline. No major third-party licensing or co-development transaction specifically involving cilofexor has been publicly established in the cited sources. The absence of a visible licensing deal reduces evidence of external validation but does not determine clinical value.

A future partnership would most likely involve:

  • A hepatology company with PSC commercialization infrastructure.
  • A regional license for China, Japan or Europe.
  • A combination-development agreement with an obesity or metabolic-disease company.
  • An asset sale if Gilead narrows its internal liver pipeline.

Key Takeaways

  • Cilofexor is an oral, nonsteroidal FXR agonist owned and developed by Gilead Sciences.
  • Its most credible remaining opportunity is PSC, not standalone MASH.
  • The drug has no FDA approval, Orange Book listing, commercial sales or active Paragraph IV generic challenge.
  • Public Phase 2 data support biomarker activity but have not established a registration-ready clinical benefit.
  • The likely core composition patent period runs into approximately 2032-2034, subject to jurisdiction-specific adjustments.
  • PSC peak sales could reach roughly $200 million-$600 million in a base commercial scenario.
  • MASH sales could be larger only if cilofexor is revived as part of a differentiated combination.
  • Resmetirom and incretin-based therapies make the MASH competitive environment materially less favorable.
  • The main investment variable is whether Gilead commits to a late-stage PSC program.

FAQs

Is cilofexor approved for primary sclerosing cholangitis?

No. Cilofexor has not received FDA approval for PSC or any other indication.

Is cilofexor the same drug as obeticholic acid?

No. Both are FXR agonists, but cilofexor is a nonsteroidal compound and obeticholic acid is a steroidal FXR agonist.

Can a generic company file an ANDA for cilofexor now?

No practical ANDA challenge exists because cilofexor has no approved reference listed drug and no Orange Book listing.

Could cilofexor be combined with resmetirom?

No established clinical or commercial combination involving cilofexor and resmetirom has been publicly validated. Any such program would require new clinical development and regulatory review.

What is the biggest risk to cilofexor's value?

The main risk is development discontinuation or failure to establish a clinically meaningful PSC benefit beyond reductions in alkaline phosphatase and other biomarkers.

References

  1. ClinicalTrials.gov. (n.d.). Study of cilofexor in participants with primary sclerosing cholangitis. U.S. National Library of Medicine. https://clinicaltrials.gov/

  2. ClinicalTrials.gov. (n.d.). Studies of cilofexor in participants with nonalcoholic steatohepatitis. U.S. National Library of Medicine. https://clinicaltrials.gov/

  3. Gilead Sciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://www.gilead.com/

  4. U.S. Food and Drug Administration. (2024). FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov/

  5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

  6. U.S. Patent and Trademark Office. (n.d.). Patent term calculator and patent examination resources. https://www.uspto.gov/

  7. Gilead Sciences, Inc. (n.d.). Pipeline. https://www.gilead.com/science-and-medicine/pipeline

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.